Original title: Multi-ligand simultaneous docking of Carica papaya leaf phytochemicals, Carpaine and Rutin, reveals multi-mechanism inhibition of cancer proteins BCL-2 and WWP1
Merla Sudha, Asmita Saha, Belaguppa Manjunath Ashwin Desai, Anil Ranu Mhashal +1 · September 2026
Cancer treatments often fail because tumors resist chemotherapy, and high drug doses cause toxic side effects. To find safer options, researchers looked at two plant chemicals from Carica papaya leaves: Carpaine and Rutin. They used computer simulations to see how these chemicals latch onto two key cancer-driving proteins, BCL-2 and WWP1. Latching onto a protein can block it from helping cancer grow. The team tested docking both chemicals at the exact same time. On BCL-2, Carpaine and Rutin attached to different spots in the same pocket, combining their strengths to grip tighter than either chemical alone or the commercial drug Venetoclax. On WWP1, Rutin helped Carpaine bind much more tightly by latching nearby. Pairing Rutin with the cancer drug bortezomib also formed a much more stable grip on WWP1. These plant chemicals hold promise for future cancer therapies, though lab experiments are still needed.
Imagine two people trying to open a heavy door. One pushes at the handle, the other pushes at the bottom. Together they open it more easily than either alone. In this paper, the two plant compounds bind to different spots on the same cancer protein, making the protein inactive more effectively than a single compound or a current drug.
Cancer treatments often fail because tumors become resistant or drugs are too toxic. This study suggests that two natural compounds from papaya leaves can block cancer proteins more effectively than a current drug, potentially leading to safer combination therapies. Patients and doctors could benefit from new options that are less harmful and more powerful.
The study is purely computational; the results have not been validated in living cells or animals. Only two proteins (BCL-2 and WWP1) and two compounds (Carpaine and Rutin) plus bortezomib were tested. No data on toxicity, bioavailability, or side effects are provided. Experimental confirmation is needed before any therapeutic claims can be made.
Ask anything about this paper. Answers come from its abstract, and say so when the abstract doesn't cover your question.
Multi-ligand simultaneous docking of Carica papaya leaf phytochemicals, Carpaine and Rutin, reveals multi-mechanism inhibition of cancer proteins BCL-2 and WWP1 — Merla Sudha, Asmita Saha, Belaguppa Manjunath Ashwin Desai et al.
Abstract licence: CC0
Explanation generated by Synthesis from the abstract — it is not the original paper. This is a preprint, so it hasn't necessarily been peer reviewed.